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ABSTRACT Parkinson’s disease is a neurodegenerative disorder characterized by
the accumulation of intracellular aggregates of misfolded alpha-synuclein along the
cerebral axis. Several studies report the association between intestinal dysbiosis and
Parkinson’s disease, although a cause-effect relationship remains to be established.
Herein, the gut microbiota composition of 64 Italian patients with Parkinson’s dis-
ease and 51 controls was determined using a next-generation sequencing approach.
A real metagenomics shape based on gas chromatography-mass spectrometry was
also investigated. The most significant changes within the Parkinson’s disease group
highlighted a reduction in bacterial taxa, which are linked to anti-inflammatory/neu-
roprotective effects, particularly in the Lachnospiraceae family and key members,
such as Butyrivibrio, Pseudobutyrivibrio, Coprococcus, and Blautia. The direct evalua-
tion of fecal metabolites revealed changes in several classes of metabolites. Changes
were seen in lipids (linoleic acid, oleic acid, succinic acid, and sebacic acid), vitamins
(pantothenic acid and nicotinic acid), amino acids (isoleucine, leucine, phenylalanine,
glutamic acid, and pyroglutamic acid) and other organic compounds (cadaverine,
ethanolamine, and hydroxy propionic acid). Most modified metabolites strongly cor-
related with the abundance of members belonging to the Lachnospiraceae family,
suggesting that these gut bacteria correlate with altered metabolism rates in Parkin-
son’s disease.
IMPORTANCE To our knowledge, this is one of the few studies thus far that corre-
lates the composition of the gut microbiota with the direct analysis of fecal metabo-
lites in patients with Parkinson’s disease. Overall, our data highlight microbiota mod-
ifications correlated with numerous fecal metabolites. This suggests that Parkinson’s
disease is associated with gut dysregulation that involves a synergistic relationship
between gut microbes and several bacterial metabolites favoring altered homeosta-
sis. Interestingly, a reduction of short-chain fatty acid (SCFA)-producing bacteria in-
fluenced the shape of the metabolomics profile, affecting several metabolites with
potential protective effects in the Parkinson group. On the other hand, the extensive
impact that intestinal dysbiosis has at the level of numerous metabolic pathways
could encourage the identification of specific biomarkers for the diagnosis and treat-
ment of Parkinson’s disease, also in light of the effect that specific drugs have on
the composition of the intestinal microbiota.
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Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the intra-cellular accumulation of -synuclein (-syn) aggregates (Lewy bodies) at various
levels of the cerebral axis, including the central nervous system (CNS) and the enteric
nervous system (ENS) (1). Clinical and neuropathological evidence indicates that the
neurodegenerative changes in PD are accompanied by gastrointestinal (GI) dysregula-
tion; however, whether this precedes or follows motor impairment remains to be
established (2). Constipation is the most common premotor symptom in PD; it can
affect more than 70% of PD patients (3) and can promote pathogenesis more than 10
years before the onset of clinical symptoms (2). Nevertheless, accumulation and ag-
gregation of misfolded -syn in the gut, coupled with neurodegeneration in the ENS
(4), seems to start up to 20 years before the onset of neurodegeneration in the CNS (5),
thus supporting the “gut-to-brain” hypothesis (6). Interactions between the intestine
and brain are known to be modulated by the intestinal microbiota through immuno-
logical, neuroendocrine, and direct neurochemical mechanisms (7). Gut bacteria and
bacterial metabolites could play a role in the pathogenesis of PD by promoting a
proinflammatory environment in the gut (8, 9). Furthermore, intestinal inflammation
associated with dysbiosis may contribute to the misfolding of -syn (10, 11).
Recently, different studies have described gut microbial alterations associated with
PD patients. The results are somewhat heterogeneous, and there is no explicit agree-
ment about which bacteria community might be involved (12–20).
Moreover, gut microbiota modifications could reflect changes in bacterial metabo-
lites. To date, several studies have investigated the metabolomics profile of PD patients
in different biological samples, such as cerebrospinal fluid, blood, and urine (21–26).
However, only a few studies have explored the fecal metabolome that mirrors the
status of colonic bacteria and also links the symbiotic microbiota and health. A better
understanding of the microbiota and metabolomics profile in fecal samples could
elucidate the interactions between host/bacterial metabolisms, gut microbes, and
disease. In turn, this knowledge may provide critical information for the implementa-
tion of better diet in PD.
Therefore, this study aimed to investigate the composition and structure of the fecal
microbiota in a cohort of Italian PD patients (PDs) compared to healthy subjects (HCs)
using 16S rRNA gene sequencing. Furthermore, intending to understand the functional
contribution of the microbial community, we used direct analysis of the fecal metabo-
lome to identify potential metabolic alterations associated with the microbiota in PD
patients.
RESULTS
Patients with Parkinson’s disease display altered microbiota composition com-
pared to healthy subjects. Characteristics of the 64 patients with PD and 51 HCs are
shown in Table 1. The bacterial communities in the PD patients and controls were
analyzed at different taxonomic levels. Firmicutes, Bacteroidetes, Proteobacteria, Actino-
bacteria, and Verrucomicrobia were the five most abundant phyla, and altogether, they
comprised more than 96% of all sequences. We detected no significant differences
between cases and controls in alpha-diversity (species richness of a group) indexes
(P  0.05) (data not shown). We also assessed potential community-level differences
between samples using beta-diversity analysis, and the weighted and unweighted
dissimilarity significantly differed between cases and controls (R2 0.079, P  0.001,
weighted; R2 0.028, P 0.001, unweighted) (Fig. 1b and c). The Mann-Whitney U test
followed by the Benjamini and Hochberg false discovery rate (FDR) correction test for
multiple comparisons was implemented to identify the different taxa within the groups.
The FDR-corrected significant differences were also plotted using linear discriminant
analysis (LDA) effect size (LEfSe) method (Fig. 2). The relative abundance of each taxon
in the two study groups is reported in Table 2. Actinobacteria, Proteobacteria, and
Verrucomicrobia were significantly enriched in diseased subjects, while Bacteroidetes
and Cyanobacteria were significantly decreased; also, members of the Firmicutes were
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decreased; however, there was no significant difference in distribution between the PD
and HC groups (P  0.05).
A total of 225 families in PDs and 217 in HCs were detected. The abundance of 16
families was significantly modified in PDs versus HCs. For instance, among the most
relevant in PDs, Verrucomicrobiaceae, Bifidobacteriaceae, Streptococcaceae, and Desulfo-
halobiaceae were increased, while Bacteroidaceae, Lachnospiraceae, Brevibacteriaceae,
and Sphingobacteriaceae families were reduced. Differences were also observed at the
genus level (601 in PDs versus 563 in HCs). The microbiota of PD patients was
characterized by significantly higher levels of several genera, such as Akkermansia,






Age (yr), mean  SD 71.39  10.99 51.67  12.42
BMI, mean  SD 26.07  4.18 23.70  3.46
Sex, n (%)
Male 44 (68.75) 31 (60.78)
Female 20 (31.25) 20 (39.22)
Constipation, n (%) 37 (57.81) 0 (0)
Coffee consumption, n (%)
Yes 40 (62.50) 44 (86.27)
No 24 (37.50) 7 (13.73)
Smoking status, n (%)
Yes 7 (10.94) 18 (35.29)







aPD, Parkinson’s disease; n, case number; SD, standard deviation; BMI, body mass index; L-DOPA,
L-3,4-dihydroxyphenylalanine.
FIG 1 Beta-diversity analysis was presented as a two-dimensional (2D) plot based on principal coordinate analysis (PCoA). The statistical significance was
assessed using permutational multivariate analysis of variance (PERMANOVA). (a) Bray Curtis (P 0.001; F 4.217; R2 0.036); (b) UniFrac weighted (P 0.001;
F  9.628; R2  0.079); (c) UniFrac unweighted (P  0.001; F  3.255; R2  0.028). CTRL, control.
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Escherichia, Bifidobacterium, Streptococcus, Clostridium, and Serratia. An increase in
some genera, such as Veillonella, Prosthecobacter, Enterobacter, and Slackia, was also
observed. In contrast, several genera were significantly reduced: Bacteroides, Blautia,
Lachnospira, Butyrivibrio, Roseburia, Pseudobutyrivibrio, Brevibacterium, Dolichospermum,
Coprococcus, and Odoribacter.
Interestingly, within Firmicutes, the major differences concerned Lachnospiraceae,
whose different genera were significantly reduced in the PD group.
As for Bacteroidetes, the major reductions concerned Bacteroidaceae and members
therein. An overview of abundant taxa of the gut microbiota composition from each PD
and healthy subject is represented as a heat map using statistical analysis of metag-
enomic profiles (STAMP) software (Fig. 3).
The analysis for confounding factors was performed using the generalized linear
model (GLM) that was adjusted for sex, age, body mass index (BMI), coffee consump-
tion, and smoking. No differences were observed in terms of the Mediterranean diet
among the different participants recruited for this study. GLM analysis confirmed only,
in part, the results obtained by the univariate analysis, indicating that some confound-
ing factors influenced the microbiota community of our samples. The statistically
significant differences in the composition of the intestinal microbiota in the PD group
compared to the HC group were, however, maintained at various taxonomic levels
(Table 3). In particular, Lachnospiraceae was significantly depleted in PD patients.
FIG 2 LEfSE analysis. The plot was generated using a Galaxy computational tool. (a) The bar plots represent the significantly differential taxa between PD
patients (green) and controls (ctrl) (red), based on effect size (LDA score [log 10] 2). Enriched taxa in PD patients (positive LDA score) and enriched taxa in
controls (negative LDA score). Differences among classes were obtained by the Kruskal-Wallis test ( 0.05). (b) Cladogram showed the differences in enriched
taxa in PD (green) versus enriched taxa in controls (red). Differences among classes were obtained by the Kruskal-Wallis test (  0.05).
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TABLE 2 Statistically significant differences in bacterial taxa between PD patients versus healthy controlsa






Caldicellulosiruptor 1 0.226 0.121 0.058 0.010 0.014
Veillonellaceae Veillonella 1 0.599 1.994 0.277 0.000 0.000
Clostridiaceae Clostridium 1 0.169 3.133 2.154 0.012 0.016
Streptococcaceae 1 0.526 1.737 0.155 0.000 0.000
Streptococcus 1 0.513 1.730 0.153 0.000 0.000
Eubacteriaceae 1 0.287 0.120 0.062 0.000 0.000
Acetobacterium 1 0.273 0.115 0.059 0.000 0.000
Lachnospiraceae 2 0.253 8.000 12.460 0.001 0.002
Anaerostipes 1 0.406 0.236 0.144 0.027 0.030
Blautia 2 0.243 3.778 5.928 0.001 0.002
Lachnospira 2 0.444 0.535 1.086 0.000 0.000
Butyrivibrio 2 0.655 0.021 0.113 0.000 0.000
Roseburia 2 0.668 1.066 1.777 0.000 0.000
Pseudobutyrivibrio 2 0.562 0.160 0.444 0.000 0.000
Coprococcus 2 0.409 0.522 0.954 0.003 0.005
Bacteroidetes 2 0.269 28.546 47.455 0.000 0.000
Bacteroidaceae 2 0.297 17.454 29.910 0.000 0.000
Bacteroides 2 0.297 17.454 30.383 0.000 0.000
Odoribacteriaceae Odoribacter 2 0.432 0.191 0.331 0.001 0.002
Porphyromonadaceae Parabacteroides 2 0.245 1.858 2.269 0.046 0.050
Rikenellaceae 1 1.460 0.112 0.000 0.000 0.000
Sphingobacteriaceae 2 0.177 1.045 1.471 0.044 0.049
Proteobacteria 1 0.177 10.548 6.542 0.020 0.023
Desulfovibrionaceae Desulfovibrio 1 0.278 0.293 0.245 0.020 0.023
Desulfohalobiaceae 1 0.355 0.185 0.123 0.002 0.003
Desulfonauticus 1 0.304 0.184 0.122 0.002 0.003
Sutterellaceae Sutterella 2 0.643 0.258 0.819 0.000 0.000
Alcaligenaceae 2 0.642 0.270 0.837 0.000 0.000
Comamonadaceae 2 0.440 0.045 0.127 0.001 0.002
Enterobacteriaceae Enterobacter 1 0.559 0.404 0.173 0.001 0.002
Escherichia 1 1.003 3.737 0.259 0.000 0.000
Serratia 1 1.011 0.672 0.050 0.000 0.000
Klebsiella 2 0.723 0.668 0.961 0.000 0.000
“Candidatus
Blochmannia”
2 1.673 0.042 1.392 0.000 0.000
Actinobacteria 1 0.313 5.524 2.263 0.002 0.003
Bifidobacteriaceae 1 0.362 4.191 1.289 0.014 0.018
Bifidobacterium 1 0.356 4.173 1.288 0.016 0.020
Coriobacteriaceae 1 0.240 0.944 0.562 0.012 0.016
Slackia 1 0.309 0.309 0.158 0.001 0.002
Microbacteriaceae 1 0.441 0.677 0.333 0.000 0.000
Brevibacteriaceae 2 0.288 0.072 0.121 0.000 0.000
Brevibacterium 2 0.288 0.072 0.120 0.000 0.000
Verrucomicrobia 1 0.614 5.429 1.020 0.002 0.003
Verrucomicrobiaceae 1 0.629 5.396 1.009 0.006 0.008
Akkermansia 1 0.464 4.669 0.879 0.015 0.019
Prosthecobacter 1 0.511 0.133 0.022 0.000 0.000
Cyanobacteria 2 0.156 0.509 0.730 0.000 0.000
Aphanizomenonaceae Dolichospermum 2 1.152 0.009 0.391 0.000 0.000
aThe results were obtained by Mann-Whitney U test performed on Statistical Package for the Social Sciences (SPSS) version 25.0, followed by the Benjamini and
Hochberg false discovery rate (FDR) correction test for multiple comparisons.
b2, Significantly reduced in PD patients; 1, significantly increased in PD patients.
cMD, mean difference between the logarithmic value of relative abundance in the PD and HC groups.
dAverage relative abundance (as a percentage) of each taxon in the PD and HC groups.
eFDR-corrected P values with FDR  0.05.
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Accordingly, Blautia, Butyrivibrio, and Coprococcus were significantly reduced in the
same group of subjects, while the only alteration in terms of richness was observed in
the Veillonella genus. Concerning Proteobacteria, “Candidatus Blochmannia” was signif-
icantly reduced in PD patients. Also, Brevibacteriaceae and Brevibacterium belonging to
Actinobacteria, as well as Dolichospermum belonging to Cyanobacteria, were signifi-
cantly reduced. In our work, Bacteroidetes and Verrucomicrobia did not show any
significant difference as opposed to the results of the univariate analysis.
Evaluation of fecal metabolites reveals alterations in the gut metabolome in
PD patients. We performed a direct evaluation of fecal metabolites by gas
chromatography-mass spectrometry (GC-MS). A total of 90 metabolites were identified
FIG 3 Heat maps of microbiota composition in PD cases and controls performed using the statistical analysis of metagenomic profiles (STAMP) software. The
results were tested for statistical significance by the Mann-Whitney U test (Statistical Package for the Social Sciences Version [SPSS] 25.0) (60).
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that included organic compounds, lipids, amino acids, and vitamins. The results of the
orthogonal partial least-square discriminant analysis (OPLS-DA) model obtained from
the comparisons of PD and HC groups using multivariate statistical analysis (MVA) are
shown in Fig. 4a. OPLS-DA model quality parameters (R2Y, 0.6; Q2, 0.36) and the
respective permutation test (R2 intercept, 0.0, 0.335; Q2 intercept, 0.0, 0.187) are
shown in Fig. 4b and c, displaying the statistical validity of the analysis and indicating
distinct metabolic profiles in the two different groups (Fig. 4).
TABLE 3 Statistically significant differences of gut microbiome in PD versus HC groupsa




Firmicutes Lachnospiraceae 2 0.567 0.009 0.002
Blautia 2 0.596 0.007 0.010
Butyrivibrio 2 0.951 0.004 0.003
Coprococcus 2 0.873 0.039 0.019
Veillonellaceae Veillonella 1 1.556 0.002 0.000
Proteobacteria Enterobacteriaceae “Candidatus Blochmannia” 2 1.62 0.000 0.000
Actinobacteria Brevibacteriaceae 2 0.640 0.001 0.000
Brevibacterium 2 0.640 0.001 0.000
Cyanobacteria Aphanizomenonaceae Dolichospermum 2 1.364 0.001 0.000
aAnalysis of covariance (ANCOVA) performed using generalized linear model (GLM) followed by Bonferroni correction for multiple comparisons in Statistical Package
for the Social Sciences version (SPSS) 25.0 for Windows. The differences in microbiota composition between PD patients versus HCs were adjusted for sex, age, BMI,
coffee consumption, and smoking status covariates.
b2, Significantly reduced in PD patients; 1, significantly increased in PD patients.
cMD, mean difference between logarithmic value of relative abundance in the PD and HC groups.
dBonferroni-corrected P values with P  0.05.
FIG 4 Metabolomics multivariate statistical analysis (MVA). (a) OPLS-DA score plots of PD patients versus control subjects. (b) Validation parameters. R2X and
R2Y indicated the cumulative explained fraction of the variation of the X block and Y block for the extracted components. Q2 values indicated cumulative
predicted fraction of the variation of the Y block for the extracted components. R2 and Q2 intercept values are indicative of a valid model. (c) The permutation
test was evaluated on the corresponding partial least-square discriminant analysis (PLS-DA) model.
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Both up- and downregulation of metabolites were observed in the PD group
compared to the HC group. The PD fecal samples clearly showed higher levels of
several metabolites, such as cadaverine, ethanolamine, hydroxypropionic acid, isoleu-
cine and leucine, phenylalanine, and thymine. In contrast, linoleic acid, oleic acid,
nicotinic acid, glutamic acid, pantothenic acid, pyroglutamic acid, succinic acid, and
sebacic acid were significantly decreased (Fig. 5).
Gut microbiota and fecal metabolite alterations are significantly related in PD
patients. We correlated the different patterns of changes observed in the microbiota
composition with microbiota metabolites in PD and HC groups.
The Spearman correlation analysis showed several significant associations of gut
bacteria with metabolites in the two groups (Fig. 6). In PDs, Lachnospira, Pseudobutyr-
ivibrio, and Roseburia genera showed strong positive correlations with nicotinic acid
and pantothenic acid. Negative correlations were instead obtained between the Ser-
ratia genus and nicotinic acid, while Bifidobacterium correlated with pantothenic acid.
Streptococcaceae and Streptococcus showed positive associations with cadaverine and,
at the same time, a negative correlation with the Sphingobacteriaceae family. Negative
correlations were also observed between the Bifidobacteriaceae family, and the related
genus Bifidobacterium, with pyroglutamic acid. A positive correlation was obtained
between this amino acid and the Sphingobacteriaceae family in the HC group. Con-
versely, negative correlations were observed with this amino acid and Enterobacter and
Serratia genera. A similar trend was obtained between the Sphingobacteriaceae family
and Enterobacter genus with glutamic acid. Prosthecobacter showed a positive correla-
tion with leucine. Last, a positive correlation between Bacteroidaceae and linoleic acid
was observed.
DISCUSSION
The present study confirmed and extended previous studies by showing that the
overall composition of gut bacterial microbiota in PD patients and HCs is significantly
FIG 5 Statistically significant metabolites in fecal samples of PD patients versus control subjects comparison. Discriminant metabolites obtained with the MVA
underwent a Mann-Whitney U test with Holm-Bonferroni correction to determine which metabolites were statistically significantly different. The resulted
metabolites obtained are shown and expressed on the y axes of the graphs as ranks (data transformation in which numerical or ordinal values are replaced
by their rank when the data are sorted). The levels of significance are indicated by asterisks as follows: *, P  0.05; **, P  0.01.
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different. Moreover, evaluation of gut microbiota composition in relation to some
confounding factors showed that some of these factors influenced the microbiota
community, although the differences in the composition of the intestinal microbiota
were maintained between PDs and HCs.
In recent years, the PD research community has given increasing attention to the
alteration of gut microbiota because of its putative implication in the disease patho-
genesis (27). Several reports on this topic have shown a different abundance of distinct
bacterial taxa between PD patients and HCs. It has been postulated that this could be
due to differences in the methodologies and patient enrollment criteria. This can also
explain why data are only partially in agreement with each other (12–20).
The results presented herein show a distinctive profile of the gut microbial com-
munity in patients with PD compared to HCs. However, our results are in partial
agreement with those previously produced by others. A possible explanation is that the
statistical significance can be affected by the correction for confounders. As an exam-
ple, in the case of Firmicutes, although univariate analysis showed a significant differ-
ence between patients and controls, after correction for different covariates (age, sex,
FIG 6 The heat maps represent Spearman correlation of the relative abundance of differential bacteria,
selected by the linear discriminant analysis effect size (LEfSe) method followed by FDR correction test,
and the concentrations of metabolites, selected by the MVA, underwent a Mann-Whitney U test with
Holm-Bonferroni correction. (a) Heat map control (n 51); (b) heat map PD (n 64). The r values are
represented by gradient colors, where red and green cells indicate positive and negative correlations,
respectively. The asterisks indicate levels of significance as follows: *, P 0.05; **, P 0.01; ***, P 0.001;
****, P  0.0001.
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BMI, coffee, and smoking), it did not match even with our data. However, in PD patients,
the results showed a significant decrease in the abundance of taxa belonging to
Firmicutes, particularly in Lachnospiraceae and key members therein, such as Blautia,
Coprococcus, and Butyrivibrio. Our data are in agreement with other studies that
showed a reduction of the Lachnospiraceae family and related genera in fecal samples
from PD patients (12, 13, 18). Several members of the Lachnospiraceae family have
progressively captured attention due to their ability to produce short-chain fatty acids
(SCFAs) (28) (Table 4). Acetate, propionate, and butyrate are the primary SCFA mole-
cules produced from gut bacteria fermentation and are endowed with anti-
inflammatory properties. These metabolites appear to play an important role in or-
chestrating the function of the enteric nervous system and in promoting
gastrointestinal integrity and motility (29). A reduction of SCFAs may also contribute to
the development of gastrointestinal motility dysfunctions, thus highlighting the po-
tential role of SCFA-producing bacteria in the pathogenesis of PD. We have investigated
whether a reduction of the aforementioned SCFA producers correlates with the deple-
tion of these metabolites in fecal samples from PDs. Although the levels of butyric acid,
propionic acid, and acetic acid, in line with the microbiota profile relative to Lachno-
spiraceae members, were decreased in PD patients, no statistically significant variations
were observed after FDR correction (P 0.05). This finding is in contrast with the results
by another research group that found a reduction in the fecal SCFAs (13). One possible
explanation for this contrasting result may reside in the parallel increase we observed
of Veillonella, Akkermansia, and Clostridium genera, which are known to produce
acetate/propionate and butyrate. The enrichment of these bacteria may have caused a
shift in the final levels of SCFAs, mirroring the balance between these taxa. Moreover,
differences in the cohort studied, in terms of the number of participants (we considered
a larger cohort) and other variables, including ethnic origins and host genetics, may
also explain these discrepancies.
As mentioned earlier, we found an increase of Veillonella in the PD group. Our result
extended, at the genus level, a previous report that showed an increase of the
TABLE 4 PD-associated abundance of SCFA-producing bacteriaa
Phylum Family Genus 2/1b
FDR-
adjusted
P valuec SCFA production
Actinobacteria 1 0.003 Acetate
Bifidobacteriaceae 1 0.018 Acetate
Bifidobacterium 1 0.020 Acetate
Bacteroidetes 2 0.000 Propionate
Bacteroidaceae 2 0.000 Propionate
Bacteroides 2 0.000 Propionate
Odoribacteriaceae Odoribacter 2 0.002 Butyrate
Firmicutes Clostridiaceae Clostridium 1 0.016 Butyrate
Lachnospiraceaed 2 0.002 Butyrate
Blautiad 2 0.002 Butyrate
Lachnospira 2 0.000 Butyrate
Veillonellaceae Veillonellad 1 0.000 Acetate/propionate
Verrucomicrobia 1 0.003 Acetate/propionate
Verrucomicrobiaceae 1 0.008 Acetate/propionate
Akkermansia 1 0.019 Acetate/propionate
aAbundance of SCFA-producing bacteria in PD patients versus healthy controls using Mann-Whitney U test,
followed by the Benjamini and Hochberg false discovery rate (FDR) correction test for multiple comparisons
(FDR 0.05).
b2, Significantly reduced in PD patients; 1, significantly increased in PD patients.
cBonferroni-corrected P values with P  0.05.
dAbundance of SCFA-producing bacteria in PD patients versus controls adjusted for sex, age, and BMI
covariates using analysis of covariance (ANCOVA) performed using a generalized linear model (GLM)
followed by Bonferroni correction for multiple comparisons in Statistical Package for the Social Sciences
Version (SPSS) 25.0 for Windows.
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Veillonellaceae family in PD patients (14). In agreement and extending the results of
another study (30) reporting a reduction of the Brevibacteriaceae family, we also found
a decrease of the Brevibacterium genus.
Among the different changes reported, the reduction in “Candidatus Blochmannia”
and Dolichospermum genera in PD patients is of particular interest. It should be noted
that to date, none of the studies carried out on the microbiota in PDs showed changes
in Cyanobacteria, to which the Dolichospermum genus belongs. Members of Cyanobac-
teria produce a series of neurotoxins that are implicated in the protein misfolding and
aggregation phenomenon that is seen in PD and other neurodegenerative disorders
(31). However, the role of Dolichospermum is not clear, and the decrease in the
abundance of Dolichospermum in PD patients deserves further investigation concerning
its potential pathophysiological role and the effects of this reduction.
Finally, an evaluation of the fecal metabolic profile was made, and it highlighted
interesting differences between PD patients and HCs. In particular, our data from direct
analysis of fecal metabolites revealed that the metabolism of several amino acids, such
as phenylalanine, leucine, and isoleucine, was significantly increased in PD patients. A
recent paper showed that the levels of phenylalanine were increased in the plasma of
subjects with PD (32). Other work has reported that amino acid-fermenting bacteria
could modulate the distribution of amino acids in the gastrointestinal tract (33, 34) and
that altered amino acid concentrations may reveal changes in energy metabolism (35).
Accordingly, the data reported in the present study indicate a significant depletion of
energy metabolism in PD.
Notably, PD patients revealed a significant reduction of the glutamic acid derivative
pyroglutamic acid, whereas glutamic acid is a neurotransmitter implicated in PD
pathogenesis (36).
Although the results concerning the levels of glutamic acid associated with PD are
rather discordant among studies, some studies have suggested that a reduction of
glutamic acid, which is also a precursor of glutathione, may reflect an increase in
oxidative stress in the disease progression (37).
In addition to modification in amino acid metabolism, our findings highlighted an
alteration of lipid metabolism.
Interestingly, the PD group was characterized by a reduction of linoleic acid and
oleic acid. In particular, linoleic acid is an omega-6 polyunsaturated fatty acid (PUFA),
and it has been associated with protective effects. Previous studies have proposed that
a reduction of PUFA in PD models may reflect an excess of oxidative stress (38). In line
with our data, some authors reported that the serum of PD patients showed decreased
levels of several long-chain PUFAs, including linoleic acid (39).
In addition to the above reported metabolic changes, we found a reduction of B
vitamins, such as nicotinic acid (vitamin B3) and pantothenic acid (vitamin B5). Both
these vitamins can be directly produced and secreted by commensal bacteria in the
gut; they can also elicit anti-inflammatory and antioxidant activity and show protective
effects against neurodegenerative mechanisms (40, 41). The reported decrease in the
levels of both B3 and B5 vitamins strongly correlated with Lachnospira, Pseudobutyriv-
ibrio, and Roseburia genera. Several genera of intestinal Firmicutes bacteria express
crucial factors for vitamin B3 synthesis (42, 43), suggesting that these bacteria might
affect the metabolism and bioavailability of these vitamins in the gut. Vitamin B5 is the
primary precursor of coenzyme A, and its deficiency might be involved in the alteration
of the citric acid cycle, causing defective energy levels, a finding shared by several
neurodegenerative disorders, such as PD, Huntington’s disease, and Alzheimer’s disease
(44).
Concerning vitamin B3, other investigations have found a chronic vitamin B3 deficit
in PD patients (45).
A toxic effect is instead ascribed to the polyamine cadaverine (46), a product of
bacterial and human cometabolism (47), which we found to be increased in PD
patients. A recent study revealed that cadaverine is involved in the inhibition of
intestinal motility in a mouse model (48). We reported that an increased level of
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cadaverine positively correlated with the Streptococcaceae family and the related genus
Streptococcus, which are known to express cadaverine biosynthetic enzymes (49). An
increase of cadaverine may also contribute to promoting a proinflammatory environ-
ment and motility dysfunctions of the gastrointestinal tract in PD.
Overall, our data highlight that microbiota modification correlated with numerous
fecal metabolites, which is suggestive of the fact that PD is associated with gut
dysregulation. Moreover, the present findings highlight that there is a mutualistic
relationship between gut microbes and several bacterial metabolites that favor altered
gut homeostasis.
In addition, we revealed alterations of several specific microbial taxa, including the
reduction of the Lachnospiraceae family and genera therein (SCFA-producing bacteria),
whose anti-inflammatory and protective role is well known within the organism.
Our study provides an overview of the complex alterations associated with PD. Since the
interaction between gut microbiota and dopaminergic medication as well as anticholin-
ergics has only recently been recognized (18, 50), more detailed investigations are needed
and are in progress in order to establish the potential role played by gut bacteria on the
therapeutic drugs in use (51) or, vice versa, a direct influence of the drugs themselves on
microbiota modifications, as the drugs may hide the real microbiota composition in naive
untreated PD patients. In addition, such studies might lead to the identification of novel
candidate biomarkers for PD diagnosis and treatment and may provide a rationale for the
development of new complementary therapeutic strategies for PD.
MATERIALS AND METHODS
Patients and samples. The institutional review boards and human subject committees at the
participating institutions approved the study (protocol PG/2017/17817). Written or verbal informed
consent was obtained from all enrolled participants: 64 patients with diagnosed PD and 51 healthy
controls.
Patient inclusion criteria were as follows: diagnosis of idiopathic PD according to the UK Brain Bank
criteria, Hoehn and Yahr stage I to IV, age between 45 and 85 years, and stable doses of dopaminergic
treatment for at least 4 weeks before enrollment. The exclusion criteria were as follows: atypical or
secondary Parkinsonism; the use of probiotic or antibiotic supplements for the 3 months before
enrollment; the presence of a primary gastrointestinal disease; the concomitant presence of internal
medicine, neurological, or unstable psychiatric illness together with severe cognitive impairment.
Patients were evaluated by the Movement Disorder Society-sponsored revision of the Unified Parkinson’s
Disease Rating Scale (MDS-UPDRS) III and IV (motor part and motor fluctuations/dyskinesia) (52), and the
following battery of clinical scales/questionnaires: nonmotor symptom scale (NMSS) (53), Scale for
Outcome in Parkinson’s disease-autonomic (SCOPA-AUT) (53), and Cognitive Assessment Montreal
(MoCA) (54). Patients were classified as either tremor dominant (TD), with postural instability and gait
difficulty (rigid-akinetic) (PIGD), or as dyskinetic patients. Stool samples from each subject were collected
at outpatient facilities of the AO Brotzu and AOU Cagliari hospitals (Cagliari, Sardinia, Italy) and delivered
to the laboratory within 3 h. The control group was composed of healthy participants, selected among
spouses and family members of study patients.
Sample and library preparation and sequencing. DNA extraction and purification were performed
as previously described (46). In particular, DNA extraction from thawed fecal samples was performed
using the QIAamp DNA stool minikit following the manufacturer’s instructions (Qiagen).
A total of 115 samples were sequenced using an Illumina MiSeq system. Sequences were assigned
to operational taxonomic units (OTUs) using Quantitative Insights into Microbial Ecology (QIIME) (55). We
performed a closed-reference OTU assignment using the “uclust” software (56) with a 97% sequence
similarity threshold against Greengenes_13.8 97% OTU cluster (57) as a reference.
Barcoded amplicon libraries for sequencing on the Illumina MiSeq platform were generated using
degenerate primers targeting the bacterial V3-V4 16S rRNA region with the Nextera index kit (Illumina),
as previously described (46).
Data and statistical analysis. Analysis of the data generated on the Miseq system was carried out
using the BaseSpace 16S Metagenomics app (Illumina). Operational taxonomic unit mapping to the
Greengenes database (V.13.8) was performed using the QIIME platform (V.1.8.0). Alpha-diversity analysis
(Shannon, Simpson, Fisher, Chao1, and abundance-based coverage estimator [ACE]), was performed on
the Microbiome Analyst tool (58). For beta-diversity analysis, weighted and unweighted UniFrac and
Bray-Curtis distances were calculated using Adonis in vegan R package (59).
The Mann-Whitney U test followed by FDR correction test for multiple comparisons was used to
identify bacterial taxa that were statistically different among PD patients and controls.
Linear discriminant analysis effect size (LEfSE) (http://huttenhower.sph.harvard.edu/galaxy/) analysis
was performed on a Galaxy computational tool to estimate the effect size of each differentially abundant
feature. Results were then corrected by FDR correction test for multiple comparisons. Heat maps of gut
microbiota composition were generated using STAMP software.
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The GLM was implemented, followed by Bonferroni correction for multiple comparisons using
Statistical Package for the Social Sciences version (SPSS) 25.0 for Windows (60), to test for confounding
factors. Only bacteria that were found to be significant at the univariate level after FDR correction were
considered. No normally distributed variables had been normalized using their logarithmic value before
performing GLM. The differences in microbiota composition between cases and controls were adjusted
for sex, age, BMI, coffee consumption, and smoking status covariates.
Microbiota and metabolome analyses. Fecal microbiota analysis was investigated as previously
described (46). For metabolomics, frozen feces were mixed in methanol solution and sonicated. After
centrifugation, the supernatants were dried and derivatized with methoxyamine dissolved in pyridine
(Sigma-Aldrich, St. Louis, MO, USA). N-Methyl-N-(trimethylsilyl)-trifluoroacetamide (Sigma-Aldrich, St.
Louis, MO, USA) was added, and the samples were resuspended in hexane and filtered. Then, 20 l from
each sample was used to create a pool for quality control.
For gas chromatography-mass spectrometry (GC-MS) analysis, 1 l of the derivatized sample was
injected splitless into a 7890A gas chromatography coupled with a 5975C network mass spectrometer
(Agilent Technologies, Santa Clara, CA, USA) equipped with a fused silica capillary column. The gas flow
rate through the column was 1 ml/min. Identification of metabolites was performed using the standard
National Institute of Standards and Technology NIST 08 standard and Golm Metabolome Database (GMD)
mass spectra libraries and by comparison with authentic standards. Data processing was performed
using a pipeline in KNIME.
The multivariate statistical analysis, PLS-DA, and OPLS-DA were performed using SIMCA-P software
(ver. 14.0; Umetrics, Sweden). GraphPad Prism software (version 7.01; GraphPad Software, CA, USA) was
used to perform the Mann-Whitney U test with Holm-Bonferroni corrected P values and Spearman
correlations between the microbiome and the metabolome.
Data availability. Sequencing data have been deposited in the European Nucleotide Archive (ENA)
under the accession number PRJEB30401. Metadata have been deposited under the accession number
PRJEB36138.
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